Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Motilal Oswal Securities Ltd.
$46.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Lupin Ltd receives FDA approval for generic Mycobutin Capsules


Wednesday, 26 Feb 2014 05:30am EST 

Lupin Ltd:Says that it has received final approval for its Rifabutin Capsules USP, 150 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Pharmacia and Upjohn company‚Äôs Mycobutin Capsules 150 mg. 

Company Quote

1345.3
-11.1 -0.82%
6:29am EDT